Alphagenics License Agreement
Tuesday, November 13th, 2007Grant Life Sciences in-licenses HPV DNA-based test from Alphagenics
“This agreement now makes us exclusive licensee of the Alphagenics HPV DNA-based test in China, a country in which there is a very high incidence, unfortunately, of cervical cancer.”
- Hun-Chi Lin, Ph.D., President and Chief Scientist, Grant Life Sciences
LOS ANGELES, Nov. 13, 2007—Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has signed a final agreement with Alphagenics Diaco Biotechnologies S.r.l. (Italy) to exclusively in-license the manufacturing and marketing rights to Alphagenics’ molecular diagnostic test for human papillomaviruses (HPVs) in China and the United States and non-exclusively in all other countries. The Alphagenics HPV test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories. Alphagenics’ HPV DNA test complements the HPV blood test that Grant has been developing to detect the presence of antibodies produced only by cancer-causing HPV types. There are some 100 types of HPV; however, only about 7 to 15 HPV-types cause most cervical cancers. While a blood-based test to detect precancerous evidence and cancer of the cervix is still viewed by Grant Life Sciences as the preferred test-methodology to address the needs of the developing world, molecular (DNA) testing is currently the approved test protocol in both the U.S. and Europe to identify the presence of different subtypes of HPV in the cervix. Read More (PDF)
